ENTR-601-51 — IND submission
2026
The Company expects to submit global regulatory applications for ENTR-601-51 in 2026.Source filing
TRDA biotech catalysts & pipeline
ENTRADA THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
VX-670 — Clinical data readout
in H2 2026
-- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 --Source filing
ENTR-601-50 — IND submission
Late 2026
The Company expects to submit regulatory applications and obtain authorization in the EU for ENTR-601-50 by year-end 2026.Source filing
ENTR-601-44 — Clinical data readout
Oct 2026
The Company expects to report data from the Cohort 1 MAD (5 mg/kg) in October 2026, data from the Cohort 2 MAD (10 mg/kg) in the first half of 2027, and data from Cohort 3 (up to 15 mg/kg) will follow, if needed.Source filing
ENTR-601-44 — Topline data
Q1 2027
In addition to the ELEVATE-44-201 Cohort 1 results included in this Quarterly Report, we anticipate reporting additional ELEVATE-44-201 Cohort 1 open-label data by the end of 2026 and topline results from the second cohort of our ELEVATE-44-201 trial in the first quarter of 2027.Source filing
ENTR-601-45 — Clinical data readout
H1 2027
The Company is on track to report data from Cohort 2 (10 mg/kg) in the first half of 2027, with data from Cohort 3 (up to 15 mg/kg) to follow.Source filing